Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Nov 19, 2021 7:54am
171 Views
Post# 34144572

RE:RE:RE:RE:RE:New post on LinkedIn

RE:RE:RE:RE:RE:New post on LinkedIn

Paul was a lot more down to earth and made reference to a large US investor who was very impressed with the pre vlinical data

Paul said the money to fund the clinical trials and  beyond will be coming as long as data in oncology and Nash are good

palinc2000 wrote:

I just viewed the tv report and I am frankly disgusted by how it was presented and by what was said.The journalist starts by addressing his comments to those who have received a cancer diagnostic today and giving high hope for a cure.
 

I dont mind some hype targeting investors and potential investors but what I saw and heard wasn't about investing ....it was about giving not only hope but HIGH hope to those suffering ftom cancer

Beliveau should show some restraint ....the audience to such tv program is not very sophisticated and he should have known



<< Previous
Bullboard Posts
Next >>